Wall Street analysts forecast that LivaNova PLC (NASDAQ:LIVN) will announce sales of $274.10 million for the current quarter, Zacks reports. Three analysts have issued estimates for LivaNova’s earnings. The highest sales estimate is $276.30 million and the lowest is $271.50 million. LivaNova reported sales of $287.50 million in the same quarter last year, which would suggest a negative year over year growth rate of 4.7%. The business is scheduled to announce its next quarterly earnings report on Wednesday, August 7th.
On average, analysts expect that LivaNova will report full-year sales of $1.11 billion for the current fiscal year, with estimates ranging from $1.10 billion to $1.11 billion. For the next year, analysts forecast that the firm will report sales of $1.18 billion, with estimates ranging from $1.16 billion to $1.19 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover LivaNova.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.54 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.11. LivaNova had a negative net margin of 19.64% and a positive return on equity of 9.38%. The company had revenue of $250.80 million during the quarter, compared to the consensus estimate of $254.89 million. During the same quarter in the prior year, the company posted $0.68 EPS. The company’s quarterly revenue was up .2% compared to the same quarter last year.
A number of research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $87.00 price objective on shares of LivaNova in a research note on Wednesday, May 15th. BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research note on Thursday, May 2nd. Piper Jaffray Companies dropped their price objective on shares of LivaNova from $120.00 to $90.00 and set an “in-line” rating for the company in a research note on Wednesday, May 1st. Zacks Investment Research downgraded shares of LivaNova from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $100.00 price objective on shares of LivaNova in a research note on Friday, April 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $106.40.
Shares of NASDAQ LIVN traded up $0.91 on Monday, reaching $72.27. 306,735 shares of the company traded hands, compared to its average volume of 613,253. LivaNova has a fifty-two week low of $64.80 and a fifty-two week high of $131.54. The company has a debt-to-equity ratio of 0.13, a current ratio of 0.87 and a quick ratio of 0.61. The company has a market cap of $3.57 billion, a P/E ratio of 22.80, a P/E/G ratio of 3.12 and a beta of 0.71.
In related news, Director Alfred J. Novak sold 1,300 shares of the stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $70.63, for a total transaction of $91,819.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William A. Kozy bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were acquired at an average cost of $72.81 per share, with a total value of $72,810.00. The disclosure for this purchase can be found here. 0.41% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Redmile Group LLC boosted its stake in shares of LivaNova by 13.1% during the 1st quarter. Redmile Group LLC now owns 582,687 shares of the company’s stock valued at $56,666,000 after buying an additional 67,700 shares during the last quarter. BlueMountain Capital Management LLC boosted its stake in shares of LivaNova by 1,997.9% during the 1st quarter. BlueMountain Capital Management LLC now owns 39,797 shares of the company’s stock valued at $3,870,000 after buying an additional 37,900 shares during the last quarter. Perceptive Advisors LLC purchased a new position in shares of LivaNova during the 1st quarter valued at approximately $3,890,000. Jane Street Group LLC boosted its stake in shares of LivaNova by 1,736.4% during the 1st quarter. Jane Street Group LLC now owns 40,971 shares of the company’s stock valued at $3,984,000 after buying an additional 38,740 shares during the last quarter. Finally, Maverick Capital Ltd. boosted its stake in shares of LivaNova by 6.0% during the 1st quarter. Maverick Capital Ltd. now owns 58,660 shares of the company’s stock valued at $5,705,000 after buying an additional 3,330 shares during the last quarter. 84.89% of the stock is owned by hedge funds and other institutional investors.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV?) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Featured Article: What is the Beige Book?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.